Targeting the protein kinase C family: are we there yet? - PubMed (original) (raw)
Review
doi: 10.1038/nrc2168.
Affiliations
- PMID: 17585335
- DOI: 10.1038/nrc2168
Review
Targeting the protein kinase C family: are we there yet?
Helen J Mackay et al. Nat Rev Cancer. 2007 Jul.
Erratum in
- Nat Rev Cancer. 2008 Mar;8(3):nrc2350
Abstract
Protein kinase C (PKC) comprises a family of serine/threonine kinases that are involved in the transduction of signals for cell proliferation, differentiation, apoptosis and angiogenesis. Unsurprisingly, disruption of PKC regulation is implicated in tumorigenesis and drug resistance. PKC function is complex in this context owing to the differing roles of individual isozymes within the cell and across tumour types. Therapeutically targeting PKC isozymes is not new; however, with many of the early PKC inhibitor cytotoxic drug combinations being discarded at the phase II level, and recent phase III studies in non-small-cell lung cancer proving negative, what's going wrong?
Similar articles
- Differential activation of PKC isozymes by 14-3-3 zeta protein.
Acs P, Szallasi Z, Kazanietz MG, Blumberg PM. Acs P, et al. Biochem Biophys Res Commun. 1995 Nov 2;216(1):103-9. doi: 10.1006/bbrc.1995.2597. Biochem Biophys Res Commun. 1995. PMID: 7488074 - Pharmacological regulation of network kinetics by protein kinase C localization.
Mochly-Rosen D, Kauvar LM. Mochly-Rosen D, et al. Semin Immunol. 2000 Feb;12(1):55-61. doi: 10.1006/smim.2000.0207. Semin Immunol. 2000. PMID: 10723798 Review. - Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E. Serova M, et al. Semin Oncol. 2006 Aug;33(4):466-78. doi: 10.1053/j.seminoncol.2006.04.009. Semin Oncol. 2006. PMID: 16890801 Review. - Protein kinase C intervention: the state of play.
Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ. Roffey J, et al. Curr Opin Cell Biol. 2009 Apr;21(2):268-79. doi: 10.1016/j.ceb.2009.01.019. Epub 2009 Feb 23. Curr Opin Cell Biol. 2009. PMID: 19233632 Review. - Critical targets of protein kinase C in differentiation of tumour cells.
Watters DJ, Parsons PG. Watters DJ, et al. Biochem Pharmacol. 1999 Aug 1;58(3):383-8. doi: 10.1016/s0006-2952(99)00063-5. Biochem Pharmacol. 1999. PMID: 10424756 Review.
Cited by
- Cancer-associated mutations in protein kinase C theta are loss-of-function.
Hodapp SJ, Gravel N, Kannan N, Newton AC. Hodapp SJ, et al. Biochem J. 2024 Jun 19;481(12):759-775. doi: 10.1042/BCJ20240148. Biochem J. 2024. PMID: 38752473 Free PMC article. - An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S, Rubin SJS, Zerihun M, Qvit N. Silnitsky S, et al. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. Int J Mol Sci. 2023. PMID: 38139428 Free PMC article. Review. - Anti-Inflammatory and Antioxidant Activities of Lipophilic Fraction from Liriope platyphylla Seeds Using Network Pharmacology, Molecular Docking, and In Vitro Experiments.
Truong VL, Bae YJ, Rarison RHG, Bang JH, Park SY, Jeong WS. Truong VL, et al. Int J Mol Sci. 2023 Oct 6;24(19):14958. doi: 10.3390/ijms241914958. Int J Mol Sci. 2023. PMID: 37834406 Free PMC article. - Emerging roles of PHLPP phosphatases in lung cancer.
Xia X, Pi W, Chen M, Wang W, Cai D, Wang X, Lan Y, Yang H. Xia X, et al. Front Oncol. 2023 Jul 27;13:1216131. doi: 10.3389/fonc.2023.1216131. eCollection 2023. Front Oncol. 2023. PMID: 37576883 Free PMC article. Review. - Golgi-Targeting Anticancer Natural Products.
Khine MN, Sakurai K. Khine MN, et al. Cancers (Basel). 2023 Mar 31;15(7):2086. doi: 10.3390/cancers15072086. Cancers (Basel). 2023. PMID: 37046746 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources